Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 8/20 | 0.41 |
| ▸ | CD38 | P28907 | 2/20 | 0.37 |
| ▸ | DPP4 | P27487 | 2/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.35 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.35 |
| ▸ | KLKB1 | P03952 | 3/20 | 0.35 |
| ▸ | TNKS | O95271 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.34 |
| ▸ | MARS1 | P56192 | 1/20 | 0.33 |
| ▸ | KLK1 | P06870 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3840256 | 0.89 | CRHR1 (0.43) | CRHR1DPP4F2RL3RIPK1 | |
| SCHEMBL13617592 | 0.84 | CRHR1 (0.38) | CRHR1F2RL3KCNH2MARS1 | |
| SCHEMBL3842403 | 0.81 | CRHR1 (0.37) | CRHR1F2RL3RIPK1 | |
| SCHEMBL3843703 | 0.80 | CRHR1 (0.38) | CRHR1CD38DPP4DPP8F2RL3 | |
| SCHEMBL3845390 | 0.80 | CRHR1 (0.38) | CRHR1CD38DPP4DPP8F2RL3 | |
| SCHEMBL3367520 | 0.78 | CRHR1 (0.43) | CRHR1DPP4DPP8TNKS | |
| SCHEMBL3841756 | 0.78 | CRHR1 (0.43) | CRHR1KCNH2 | |
| SCHEMBL3846201 | 0.78 | CRHR1 (0.43) | CRHR1KCNH2 | |
| SCHEMBL3364750 | 0.77 | CRHR1 (0.48) | CRHR1CD38DPP4DPP8F2RL3 | |
| SCHEMBL3364574 | 0.77 | CRHR1 (0.50) | CRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2007753-B1 | HETEROCYCLIC GABA ALPHA SUBTYPE SELECTIVE RECEPTOR MODULATORS | HOFFMANN LA ROCHE (CH) | 2009-11-11 | — | — | EP | disclosed |
| US-20070238765-A1 | Heterocyclic GABAA subtype selective receptor modulators | ROCHE PALO ALTO LLC | 2007-10-11 | — | — | US | disclosed |
| US-20070238765-A1 | Heterocyclic GABAA subtype selective receptor modulators | ROCHE PALO ALTO LLC | 2007-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070238765-A1 | Heterocyclic GABAA subtype selective receptor modulators | GABRA1, GABRA2, GABRA3 | CRHR1 96/4885CD38 1596/4885DPP4 3627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.